| Preclinical | Phase I | Phase II | Phase III | Marketed | |
| Novel Bisplatinum Analogues | |||||
Cisplatin is a platinum-based chemotherapy drug used to treat a wide variety of cancers. We are developing new analogues of the dinuclear-platinum complex, CT-3610 that is more potent than cisplatin. CT-3610 is endowed with a unique mechanism of action, active in preclinical studies on a large panel of tumor models, sensitive and refractory to cisplatin, and has a safety profile comparable to that of cisplatin.
The novel bisplatinum analogues are rationally designed and synthesized to have improved biopharmaceutical properties that reduce the intrinsic reactivity of the molecule and that demonstrate preclinical anti-tumor efficacy in solid tumor models.
We are conducting discovery research on a number of drug targets and agents. In addition to this research, our preclinical activities are focused on product lifecycle management, including the development of alternative dosage forms for existing products in the development pipeline.